Prostate cancer is the most frequently diagnosed non-skin cancer and the second leading cause of cancer-related mortality in men in the United States. Over the past decade, the treatment landscape for advanced prostate cancer has rapidly shifted. For decades, androgen deprivation therapy has been the cornerstone of systemic treatment for patients with metastatic hormone-sensitive prostate cancer (mHSPC). However, more recently, we have seen the emergence of doublet and triplet combinations in the mHSPC setting. At the same time, there is an expanding list of treatments for patients with metastatic castration-resistant prostate cancer (mCRPC), including hormonal treatments, chemotherapy, immunotherapy, bone-targeted agents, radioligand therapy, and targeted therapy. The shifting of the treatment landscape for advanced prostate cancer has raised many questions regarding patient selection, therapy choice, and sequencing of different approved agents, particularly in the mCRPC setting with the earlier use of chemotherapy and androgen receptor signaling inhibitors. Since then, multiple trials have been conducted to improve the management of mHSPC and delay its progression to mCRPC. This review article discusses various clinical trials that focus on novel therapeutic targets for prostate cancer and how the initiation of newer clinical trials has affected older therapies and trials.
Clinical advances in hematology & oncology : H&O. 2023 Jun [Epub]
Chinmay Jani, Nour Abdallah, Pavlina Chrysafi, Christian Mouchati, Daniel Herchenhorn, Rana R McKay
Department of Medicine, Mount Auburn Hospital, Cambridge, Massachusetts., Department of Urology Research, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio., School of Medicine, Case Western Reserve University, Cleveland, Ohio., University of California San Diego, San Diego, California.